Abstract:Background:The Yes-Associated Protein (YAP) is a central regulator of Hippo pathway involved in carcinogenesis, which functions through interaction with TEA Domain (TEAD) transcription factors. Pharmacological disruption of YAP–TEAD4 complexes has been recognized as a potential therapeutic strategy against diverse cancers by suppressing the oncogenic activity of YAP.Objective:Two peptides, termed PS-1 and PS-2 are split from the interfacial context of YAP protein. Dynamics simulations, energetics analyses and fluorescence polarizations are employed to characterize the intrinsic disorder as well as binding energy/affinity of the two YAP peptides to TEAD4 protein.Methods:Two peptides, termed PS-1 and PS-2 are split from the interfacial context of YAP protein. Dynamics simulations, energetics analyses and fluorescence polarizations are employed to characterize the intrinsic disorder as well as binding energy/affinity of the two YAP peptides to TEAD4 protein.Result:The native conformation of PS-2 peptide is a cyclic loop, which is supposed to be constrained by adding a disulfide bond across the spatially vicinal residue pair Arg87-Phe96 or Met86- Phe95 at the peptide’s two ends, consequently resulting in two intramolecular cyclized counterparts of linear PS-2 peptide, namely PS-2(cyc87,96) and PS-2(cyc86,95). The linear PS-2 peptide is determined as a weak binder of TEAD4 (Kd= 190 μM), while the two cyclic PS-2(cyc87,96) and PS-2(cyc86,95) peptides are measured to have moderate or high affinity towards TEAD4 (Kd= 21 and 45 μM, respectively).Conclusion:PS-1 and PS-2 peptides are highly flexible and cannot maintain in native active conformation when splitting from the interfacial context, and thus would incur a considerable entropy penalty upon rebinding to the interface. Cyclization does not influence the direct interaction between PS-2 peptide and TEAD4 protein, but can largely reduce the intrinsic disorder of PS-2 peptide in free state and considerably minimize indirect entropy effect upon the peptide binding.

Computational design and experimental confirmation of a disulfide-stapled YAP helixα1-trap derived from TEAD4 helical hairpin to selectively capture YAP α1-helix with potent antitumor activity

Targeting Yap/Taz-Tead Protein-Protein Interactions Using Fragment-Based And Computational Modeling Approaches

Structural Basis of YAP Recognition by TEAD4 in the Hippo Pathway.

Targeting Hippo Pathway by Specific Interruption of YAP‐TEAD Interaction Using Cyclic YAP‐like Peptides

Structural Insights into the YAP and TEAD Complex.

Targeting Human Hippo TEAD Binding Interface with YAP/TAZ-Derived, Flexibility-Reduced Peptides in Gastric Cancer

Structural and Functional Analysis of the YAP-binding Domain of Human TEAD 2

Direct inhibition of the YAP:TEAD interaction: an unprecedented drug discovery challenge

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

TEAD Mediates YAP-dependent Gene Induction and Growth Control

TAZ‐hTrap: A Rationally Designed, Disulfide‐Stapled Tead Helical Hairpin Trap to Selectively Capture Hippo Signaling Taz With Potent Antigynecological Tumor Activity

YAP/TAZ for Cancer Therapy: Opportunities and Challenges (Review).

Covalent disruptor of YAP-TEAD association suppresses defective hippo signaling

Rational design and chemical modification of TEAD coactivator peptides to target hippo signaling pathway against gastrointestinal cancers

Rational Design and Intramolecular Cyclization of Hotspot Peptide Segments at YAP-TEAD4 Complex Interface

Abstract 4516: Inhibiting YAP activity in cancers by targeted degradation of TEAD

Abstract B11: Computational Insights on the Druggability of TEAD YAP-binding Domain

Abstract IA18: Targeting the Hippo Pathway for Candidate Cancer Therapy

Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors

Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway

Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex